on INTEGRAGEN (EPA:ALINT)
IntegraGen revenue down for 2024
IntegraGen, a company specializing in genomics, announces a turnover of 8.5 million euros for 2024, a decrease of 27% compared to 2023. This decrease results mainly from the cessation of services for the SeqOIA platform, which generated 858,000 euros in 2024 compared to 4.365 million in 2023.
On the other hand, excluding the SeqOIA platform, revenues increased by 5%, with a notable increase in genomic services of +8% in Évry. Cash flow stabilized at €1.9 million, down by €1 million compared to last year, impacted by a drop in revenues and variations in payment terms.
IntegraGen is nevertheless looking to a growth perspective supported by multi-year contracts and the obtaining of CLIA certification, which expands its market to the pharmaceutical industry.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INTEGRAGEN news